DEFA14A 1 ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 14A

(Rule 14a-101)

PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE

SECURITIES EXCHANGE ACT OF 1934

Filed by the Registrant x Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨ |  | Preliminary Proxy Statement
¨ |  | Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨ |  | Definitive Proxy Statement
x |  | Definitive Additional Materials
¨ |  | Soliciting Material Pursuant to § 240.14a-12
Cryo-Cell International, Inc.
(Name of Registrant as Specified in its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
x |  | No fee required.
¨ |  | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
|  | (1) |  | Title of each class of securities to which transaction applies:
|  | (2) |  | Aggregate number of securities to which transaction applies:
|  | (3) |  | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
|  | (4) |  | Proposed maximum aggregate value of transaction:
|  | (5) |  | Total fee paid:
¨ |  | Fee paid previously with preliminary materials.
¨ |  | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
|  | (1) |  | Amount previously paid:
|  | (2) |  | Form, Schedule or Registration Statement No.:
|  | (3) |  | Filing Party:
|  | (4) |  | Date Filed:

August 9, 2011 Presentation to ISS Review of Performance and Shareholder Value Creation Ms. Mercedes Walton Mr. Anthony Finch Ms. Jill Taymans

Statements wherein the terms “believes”, “intends”, “projects” or “expects” as used are intended to reflect “forward-looking statements” of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward- looking statements or paragraphs. Readers/Audience should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and any Current Reports on Form 8-K filed by the Company. FORWARD-LOOKING STATEMENTS

COMPANY & INDUSTRY OVERVIEW

CCEL Public since 1991 11.7 million Approx. 5,000 shareholders $17.6 million $35 million Mercedes Walton, Chairman & CEO Jill Taymans, VP & Chief Financial Officer Julie Allickson, PhD, VP Lab Operations 7 members; will be 6 at next annual meeting Multi-Disciplinary: Hematology/Oncology; Infectious Disease; Stem Cell Transplant; Clinical Pathology; Transfusion Medicine; OB/GYN 1989 in Delaware Oldsmar, FL 28,000 Sq. Ft. 60 Associates OTC.QB Shares Outstanding FY’10 Annual Revenue Current Market Capitalization Officers Board of Directors Medical & Scientific Advisory Board Incorporation Headquarters PUBLIC COMPANY PROFILE

BUSINESS OVERVIEW One of the world's largest and most established cord blood stem cell banks Services U-Cord ® : Collection and cryopreservation of stem cells from umbilical cord blood Célle Collection and preservation of stem cells from menstrual Cryology Cryopreservation and transportation coordination of reproductive tissue U-Cord ® Plus Cord tissue and cord blood stem cell cryopreservation Client Base Over 235,000 worldwide Markets Served United States Mexico, Central America, South America India, Thailand, Malaysia, China, Pakistan Revenue Sources Service fees for cord blood and menstrual fluid collection and preservation Recurring annual storage fees Licensing fees and royalties from global affiliates fluid (MenSC) : : :

U.S. CORD BLOOD BANKING MARKET DYNAMICS (1) Based on target demographics (2) Based on target market. First Call research estimates Large and Growing Market 4 million annual births Target market: 800,000 to 1,000,000 annually (1) Low Penetration Rate Current annual penetration rate: less than 8.0% (2) Highly-Fragmented Approx. 25 competitors (of which two are publicly traded – PKN and CBAI) 3 companies hold 75 - 80% market share High Barriers to Entry Increased government regulation Significant capital investment High costs of operation Increasing presence of public cord blood banks

CRYO-CELL PERFORMANCE HIGHLIGHTS: FY2010 • Proven Financial Performance • Cash Flow Positive • Growing installed base • Technology License Royalties • Strong cash position • No long-term debt • Expansive IP Portfolio U-CORD® SPECIMENS PROCESSED AND STORED (CUMULATIVE)

Established Client Base - Loyal customer base driving repeat business and client referrals Expanding Global Presence - Leveraging turnkey business model Highly Differentiated Marketing Message - Potential therapeutic applications for major diseases increasing interest and value of stem cell banking Targeted Marketing Initiatives – Leveraging highly scalable internet marketing, call center support and clinical services strategies to target and grow consumer and professional markets Product Diversification – Introduced Célle service in November 2007. and commenced pre-clinical studies of the technology: “Protect Baby, Protect Mom” Proprietary IP – Several MenSC research & development collaborations underway by strategic alliances/partners utilizing Cryo-Cell’s proprietary technology CRYO-CELL GROWTH DRIVERS

STOCK PRICE PERFORMANCE

STOCK PRICE PERFORMANCE

STOCK PRICE PERFORMANCE Source: Capital IQ Note: Stem Cell/Cord Bank Index includes: (DB:V3V, NYSE:CO, AMEX:NBS, GTSM:1784, ENXTAM:CRYO, OTCBB:CBAI, ASX:CBB) and is an equal weighted Index

U CORD BLOOD AND CÉLLE ARE COMPLEMENTARY Umbilical Cord Blood CÉLLE Therapeutic Use: Leukemia & Lymphoma, Blood disorders, Immune diseases Currently in Pre-Clinical trials for Diabetes, Cardiac disorders, Urinary incontinence & Diagnosis of endometriosis, Wound healing, Blood vessel formation, Cell tracking in a breast cancer model, Stroke Markers Expressed: CD34, CD45 Adult MSC & ESC Markers Ease of Collection: Yes Yes Proliferative Capacity: Yes, blood Yes, undifferentiated Limited Cell Dose: Yes No

RESEARCH & DEVELOPMENT PIPELINE Partner Indication Description Status Cryopraxis Cryobiology Ltd Urinary Incontinence & Diagnosis of endometriosis Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical Snyder Wound Research Institute Wound healing Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical EndGenitor Technologies Blood Vessel Formation Umbilical cord blood and endometrial menstrual blood derived stem cells (MenSCs) Pre-clinical University of Miami Diabetes Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical Saneron CCEL Therapeutics, Inc Stroke Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical S-Evans Biosciences Various Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical Monash University Multiple Sclerosis Endometrial Menstrual Stem Cells (MenSCs) Pre-clinical

FINANCIAL SUMMARY FY 2010 FY 2009 FY 2008 FY2007 FY2006 Revenue-processing and storage $16.1M $16.3M $17.3M $17.5M $17.2M Revenue-licensee income $1.5M $1.3M $1.0M $951K $927K Gross Profit 74.5% 74.3% 64.7% 64.2% 66.5% Net Income (Loss) $3.4M $1.6M ($741K) ($5.0M) ($2.8M) Earnings (Loss)/ Share $0.29 $0.14 ($0.06) ($0.43) ($0.24) Cash & Equivalents $9.5M $8.0M $4.7M $4.4M $8.5M 117% Revenue growth, fiscal 2003 – 2010 Revenue has been flat over the last three years - Economic trends affecting discretionary consumer spending - Public cord blood banking

CRYO-CELL COMPETITIVE ADVANTAGES Proprietary IP – Célle Technology Portfolio Advancing Women’s Healthcare • Isolation of the Célle menstrual stem cell offers new therapeutic potential • Future Potential Revenues – Therapeutic Commercialization Superior Quality Accreditations • FDA registered • Fully licensed and accredited by AABB (formerly American Association Blood Banks) ; ISO 9001:2000 State-of-the-Art Manufacturing Facility Certified Current Good Manufacturing/Good Tissue Practice compliant (cGMP/cGTP) Growing Royalties From Global Affiliates Latin American Expansion (Mexico, Brazil, Venezuela, Ecuador, Panama, El Salvador, Guatemala, Honduras, Nicaragua, Chile, Colombia, Peru, Curacao, Aruba, St. Maarten) Southeast Asia (India, China, Thailand, Pakistan) Middle East (Dubai, Saudi Arabia, UAI, Kuwait, Bangladesh, Nepal, Sri Lanka, Bhutan, Maldives, Oman) Europe (Italy, Germany, Spain, UK, Ireland) Commercial Partnerships 35% equity stake in R&D partner, Saneron CCEL Therapeutics, Inc. and worldwide marketing rights to any products developed

Growth Strategy: Looking to the Future Strategic: Organic: • Global affiliate growth • “Next Generation” services • Further diversification of service offering • Highly differentiated platform for women’s healthcare • R&D platform • Geographical expansion • Expansion of IP portfolio • Technology license opportunities • Clinical development • M&A opportunities

The Future is Bright To summarize, Cryo-Cell has: Over 235,000 clients worldwide 24 global license affiliates Célle, the world's only menstrual stem cell service An expansive intellectual property portfolio of proprietary menstrual stem cell technology Strategic partnerships with globally renowned stem cell researchers Unprecedented self-funded research and development business model Expanded new services including Protect Baby, Protect Mom® U-Cord Plus®, P3®, and Cryology Reproductive Tissue Storage® Ten consecutive quarters of operating profitability and two consecutive quarters of double-digit unit growth and revenue growth $9.3 million in cash, cash equivalents and marketable securities and no long-term debt at the end of second quarter 2011 An increase in share price of 194% year-over-year: $3.67 at the end of second quarter 2011 versus $1.25 at the end of second quarter 2010

PROXY CONTEST

THE PORTNOY GROUP David Portnoy is seeking 5 of 6 director seats Portnoy is effectively seeking to take control of Cryo-Cell without paying a control premium to shareholders Portnoy rejected the Company’s offer of one seat (which is proportionate to his group’s ownership of Cryo-Cell) The Portnoy Group does not provide Cryo-Cell or its stockholders with any plan to add shareholder value

STRONG CORPORATE GOVERNANCE PRINCIPLES The Company has an annually elected board; all but CEO are independent Cryo-Cell has an independent lead director The Audit, Compensation, and Nominating & Governance Committees are comprised solely of independent directors The Company does not have a poison pill Shareholders may act by written consent

OUR NOMINEES Scott Christian -- more than 30 years of financial management experience with companies such as Automatic Data Processing, Ceridian Corporation, Norstan, Spanlink Communications and XATA, in successively expanded roles from Senior Vice President of Finance through Chief Financial Officer to the CEO level. Experience in global communications solutions and services and deep knowledge of financial management. Andrew J. Filipowski -- entrepreneur who has founded several businesses over the past 25 years. Brings to the Cryo-Cell boardroom the perspective of a large stockholder (currenlty owns in excess of 5.5% of Cryo-Cell)

OUR NOMINEES Anthony P. Finch -- 35 years of experience in cell separation and cryopreservation of cellular products. Currently serves as Chief Scientific Officer of the Irish National Blood Centre and National Tissue Typing Reference Laboratory. Has over 20 years experience in cord blood processing and pioneered the fractionation and isolation of cord blood stem cells for small volume cryogenic storage and has developed large scale processing in line with current Good Manufacturing Practice (cGMP). Has established several cord blood stem cell banks in the United States, Europe and Asia. Brings his wealth of experience and expertise in cord blood stem research, management, organization and processing. He is a Fellow of both the Academy of Medical Laboratory Sciences and Institute of Biomedical Sciences, and is a member of the Cord Blood Stem Cell International Society. James P. Pellow Ed.D -- over 25 years of professional experience and has served as a director of public companies in various roles, including lead director, chairman of the governance committee and member of the audit committee. Has significant corporate governance experience. Serves as CEO and president of the Council on International Educational Exchange (CIEE). Served as the executive vice president and chief operating officer of St. John’s University from 1999 until May 2011 and in various other capacities since 1991. Previously was a certified public accountant with Coopers & Lybrand and a municipal bond trader with Chapdelaine & Co.

OUR NOMINEES Anthony Atala, M.D., -- 25 years of professional experience and globally recognized stem cell researcher in the area of regenerative medicine. Current work focuses on growing new human cells, tissues and organs. Serves as Director of the Wake Forest Institute for Regenerative Medicine with a team of over 160 physicians and researchers and is the W.H. Boyce Professor and Chair of the Department of Urology at Wake Forest University. Works with several journals and serves in various roles, including Editor-in-Chief of Stem Cells Translational Medicine and Current Stem Cell Research and Therapy. Has served as a director on several boards. Currently an NIH “Quantum Grant” awardee and has published more than 250 journal articles; has applied for or received over 200 national and international patents. Mercedes Walton -- 35 years of corporate management experience with significant senior executive expertise in the creation and implementation of innovative commercialization strategies for a variety of enterprises including AT&T; Applied Digital Solutions, Inc. and Digital Angel. Principal inventor on the expansive intellectual property portfolio of global patent-pending Célle menstrual stem cell technology applications assigned to the Company. Has served on the board of directors of five publicly traded companies in the biotechnology and communication services sectors.

PORTNOY’S NOMINEES In sharp contrast to the Cryo-Cell Board nominated slate, the Portnoy Group’s nominees have no relevant indicated experience in the stem cell preservation industry, business of regenerative science or relevant public company operating experience. The Portnoy Group consists of a hand- picked group of individuals who appear to have long-time personal and business relationships with David Portnoy: Mark and David Portnoy -- brothers with no known relevant experience Harold Berger -- an accountant who provides accounting services to Mark Portnoy and certain entities controlled by Mark Portnoy George Gaines -- a consultant to entities seeking to structure and raise capital for private equity funds Jonathan H. Wheeler, M.D., an OB/GYN

PORTNOY’S SLATE IS NOT QUALIFIED TO SERVE CRYO-CELL SHAREHOLDERS Portnoy’s Slate Brings: No Insight No Business Plan No Strategy No Track Record No relevant indicated experience in the stem cell preservation industry No relevant indicated experience in the business of regenerative science No relevant public company operating experience